Saxena Vandana, Dhole Tapan N
Department of Microbiology,Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226 014,India.
J Biosci. 2008 Nov;33(4):505-14. doi: 10.1007/s12038-008-0069-9.
Japanese encephalitis (JE) remains the most important cause of acute viral encephalitis and continues to spread to hitherto unaffected regions like Indonesia, Pakistan and Australia. Approximately 60% of the world population inhabits JE endemic areas. Despite its restricted range mostly in the developing countries,a high annual incidence of 50,000 cases and about 10,000 deaths has been reported. Disease can be fatal in 25% ases. Magnitude of the problem is even more alarming since the survivors are left with serious long-term neuropsychiatric sequelae. Almost every two years,epidemics of JE occur in Indian subcontinent with a high mortality. JE virus infection results in different disease manifestations in host from mild subclinical febrile illness to clinical infections leading to encephalitis. No antiviral treatment is so far available for JE. The prevention of JE can be achieved by controlling the vector or by immunization regime. The vector control in the rural areas,which are the worst affected ones,is practically almost impossible. Three vaccines that have been implicated against JE include inactivated mouse brain derived, inactivated cell culture derived and cell culture derived live attenuated JE vaccine. But each has its own limitation. Currently,attempts to synthesize recombinant DNA vaccine are being made. New therapeutics are on the way of development like use of minocycline, short interfering RNA, arctigenin, rosmarinic acid, DNAzymes etc. However,the immune mechanisms that lead to JE are complex and need to be elucidated further for the development of therapeutics as well as safe and efficacious JE vaccines.
日本脑炎(JE)仍然是急性病毒性脑炎的最重要病因,并继续蔓延到印度尼西亚、巴基斯坦和澳大利亚等迄今未受影响的地区。世界上约60%的人口居住在日本脑炎流行地区。尽管其传播范围大多局限于发展中国家,但据报道每年仍有5万例高发病率病例和约1万例死亡。25%的病例可能会致命。由于幸存者会留下严重的长期神经精神后遗症,这一问题的严重性更加令人担忧。在印度次大陆,日本脑炎几乎每两年就会爆发一次,死亡率很高。日本脑炎病毒感染在宿主中会导致不同的疾病表现,从轻微的亚临床发热疾病到导致脑炎的临床感染。目前尚无针对日本脑炎的抗病毒治疗方法。预防日本脑炎可通过控制病媒或采用免疫接种方案来实现。在受影响最严重的农村地区,病媒控制实际上几乎是不可能的。三种与日本脑炎相关的疫苗包括灭活鼠脑源疫苗、灭活细胞培养源疫苗和细胞培养源减毒活疫苗。但每种疫苗都有其自身的局限性。目前正在尝试合成重组DNA疫苗。新的治疗方法正在研发中,如使用米诺环素、短干扰RNA、牛蒡子苷元、迷迭香酸、脱氧核酶等。然而,导致日本脑炎的免疫机制很复杂,需要进一步阐明,以便开发治疗方法以及安全有效的日本脑炎疫苗。